GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum
ATLANTA, GA - April 16, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today addressed the termination of its Project NextGen (PNG) award by the Biomedical Advanced Research and Development Authority (BARDA), effective April 11, 2025. The Company also provided a comprehensive business update across its core programs, including the next-generation COVID-19 vaccine (GEO-CM04S1), cancer immunotherapy (Gedeptin(R)), Mpox/smallpox vaccine (GEO-MVA), and advanced MVA manufacturing process.
GeoVax expressed disappointment in the HHS/BARDA action but remains committed to the critical medical need addressed by GEO-CM04S1, particularly among the more than 40 million immunocompromised Americans - and over 400 million people globally - who remain inadequately protected by the current authorized COVID-19 vaccines. Thus far, clinical data in support of GEO-CM04S1 demonstrate encouraging support of the potential of GEO-CM04S1 for providing (a) more robust immune response, (b) increased durability and (c) protective immunity for those patients with depleted immune systems inadequately responding to the current authorized COVID-19 vaccines.
The Company also noted recent public statements by HHS leadership acknowledging the potential enhanced value of multi-antigen vaccines addressing respiratory viruses. Of special note is that GEO-CM04S1 was the only multi-antigen/polyvalent COVID-19 vaccine candidate selected under the PNG initiative.
'While the recent HHS/BARDA Stop Work Order action was disappointing and surprising, our commitment to protecting vulnerable populations remains unchanged, and our clinical momentum is strong in support of our ongoing Phase 2 GEO-CM04S1 programs,' said David Dodd, Chairman and CEO of GeoVax.
Continued Progress Across a Catalyst-Rich Pipeline
GEO-CM04S1: Advancing to Meet Unmet COVID-19 Needs
GEO-CM04S1 continues to demonstrate potential as both a primary and booster vaccine, especially in immunocompromised patients. Key milestones anticipated during 2025 include:
GEO-CM04S1 is a multi-antigen COVID-19 vaccine, utilizing a synthetic-MVA platform, expressing both S and N antigens, offering the potential for broader, more durable protection than current mRNA vaccines.
Gedeptin(R): Advancing into Phase 2 in Solid Tumors
GeoVax's oncology program, utilizing the Gedeptin(R) technology, is planned to progress to a Phase 2 trial in combination with an immune checkpoint inhibitor for first recurrent head and neck cancer. Gedeptin has received Orphan Drug designation for use among advanced head & neck cancer patients. The Gedeptin technology provides potential for expansion into other solid tumors including triple-negative breast cancer, melanoma, and soft tissue sarcoma.
GEO-MVA: Addressing Biosecurity and Global Vaccine Equity
GeoVax anticipates initiating clinical trials in 2025 for GEO-MVA, its Mpox/smallpox vaccine candidate. The Company has successfully produced cGMP clinical product and is focused on completing the vaccine vialing in support of initiating clinical evaluation during H2 2025. GEO-MVA positions GeoVax to offer a U.S.-developed alternative to foreign-sourced vaccines amid rising global biosecurity threats and constrained supply.
Advanced Manufacturing: Scaling MVA for Global Reach
GeoVax is advancing continuous cell line manufacturing for MVA-based vaccines, offering a path to scalable, cost-effective production - including localized manufacturing for low- and middle-income countries. This innovation addresses critical gaps in vaccine self-sufficiency and supply resilience.
Outlook for 2025
Despite the PNG award termination, GeoVax anticipates a milestone-rich 2025 across its portfolio. The Company will continue to engage with government and industry partners, pursue clinical trial completions, and drive innovation through expanded AI integration to optimize development, trial operations, and manufacturing efficiency.
'Our scientific foundation is strong and our strategy is clear,' added Dodd. 'GeoVax remains committed to delivering transformative solutions for unmet medical needs in infectious disease and cancer. We're advancing with purpose and fully prepared to deliver on the promise of our development program.'
For further details on GeoVax's programs and progress, visit www.geovax.com.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Company Contact:
[email protected]
678-384-7220
Investor Relations Contact:
[email protected]
212-698-8696
View the original release on www.newmediawire.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Axios
28 minutes ago
- Axios
These states have the highest COVID cases right now as "stratus" variant erupts
Twelve states are seeing higher positivity rates for COVID-19 tests compared to the rest of the country, according to new data from the Centers for Disease Control and Prevention. Why it matters: Positivity rates are popping off as the "stratus" COVID variant surges throughout the country Driving the news: The CDC updated its regional data for COVID-19 test positivity on Monday, Aug. 11. The data accounts for the week ending on Aug. 2. Zoom in: The states with the highest COVID test positivity include: New Mexico (12%) Texas (12%) Oklahoma (12%) Arkansas (12%) Louisiana (12%) Nevada (11.3%) Arizona (11.3%) California (11.3%) Alaska (11.1%) Washington (11.1%) Oregon (11.1%) Idaho (11.1%) Worth noting: The rest of the country's test positivity rate ranks between 5% to 9.9%. The big picture: Overall, the CDC reports that the COVID-19 epidemic trend is "growing," with 45 states experiencing an increase in cases. No state has seen a decline in cases as of Aug. 5, per the CDC. Last Friday, the CDC upgraded the national wastewater viral activity for COVID-19 from "low" to "moderate," signaling a rise in cases nationwide. Higher wastewater activity was spotted in the Southeast, with Louisiana having a "very high" amount — the most nationwide. "Stratus" COVID-19 variant rises Context: The rise in COVID-19 cases amid an uptick in cases of the XFG "stratus" variant. Though it was first detected in January, the variant now accounts for 14% of cases in the U.S., and is the third-highest among all variants stateside, according to the CDC. The World Health Organization said XFG might be more likely to evade immune defenses. However, current COVID-19 vaccines "are expected to remain effective to this variant against symptomatic and severe disease," the WHO said in its June report. How to detect "stratus" COVID symptoms
Newsweek
an hour ago
- Newsweek
Couple Take 'Romantic' Beach Pic—Horror As They Fear Danger in Plain Sight
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A woman has shared a shocking story of how she believed she almost killed her husband—by asking him to pose for a romantic photo. Aslıhan, 52, who gave her first name only, is originally from Turkey but now lives in California with her family, whom she described to Newsweek as loving "snorkeling and exploring marine life." After the associated restrictions of the COVID-19 pandemic came to an end, the family decided to celebrate with an unforgettable vacation to Bora Bora, a tranquil island in French Polynesia, famous for its luxury resorts and stunning marine life. And, one day, walking on the shore, Aslıhan said she "spotted a beautiful shell," which she picked up and placed on her husband's hand for a romantic photo, before returning it to where she found it. Aslıhan didn't think much of it again—until, years later, her kids saw a video "about deadly sea creatures," and appeared to recognize the shell from their parents' photo. When she later asked ChatGPT to identify the creature in the photo, it determined it "looked like a venomous cone snail." Cone snails, within the Conidae family, are predatory gastropod mollusks. The venom from just one snail is hypothesized to have the potential to kill up to 700 humans, according to a report published in the National Library of Medicine. Tourists may inadvertently pick up the creatures, thinking it is a harmless snail or a shell souvenir, and several humans have died from envenomation from the cone snail—with injuries most often occurring on the palms and fingers. Aslıhan's husband holds the shell she picked up on the beach. Aslıhan's husband holds the shell she picked up on the beach. Reddit u/KremKaramela Aslıhan was horrified, and took to Reddit's r/Wellthatsucks via her account u/KremKaramela on August 5, where she shared the photo and wrote: "I almost killed my husband. "I found this beautiful shell in Bora Bora and put it on my husband's hand we took a 'romantic' photo only to learn years later that its venom is deadly," she wrote, adding: "It gives me chills every time I think I put my husband's life in danger." Reddit users had a big reaction, awarding the post more than 53,000 upvotes; however, many commenters rushed to assure Aslıhan that she may not, in fact, have almost killed her husband. As one commenter put it: "This is a Mitra mitra. Not a cone snail, and not deadly. However, it's still a good reminder to not pick up random sea creatures." Another agreed: "Pretty sure this is just a mitra mitra shell, very commonly sold and I can't find anything about poison." Read more Woman picks up shell—only to learn it's one of the deadliest on Earth Woman picks up shell—only to learn it's one of the deadliest on Earth "It's almost definitely mitra mitra as others have pointed out. Absolve your guilt, your husband was safe," a third posted, adding: "It is best to not touch animals in the wild, because you really never know, but also because they deserve to live their lives without being bothered or handled by humans." And, in positive news, the Marine Biological Association (MBA) confirmed to Newsweek that the creature is indeed an episcopal miter, Mitra mitra. This species of large sea snail is harmless to humans. However, the MBA recommends that, if a member of the public needs to identify a shell, they should send an image, location and habitat to the Conchological Society email, marine@ Aslıhan told Newsweek it was "definitely a relief to hear it might not have been the deadly species, but I'm still upset with myself for possibly putting us at risk." "We haven't returned to Bora Bora since, but this experience wouldn't stop us from going back," she said. "That said, I'll never again pick up or handle any unknown marine life—lesson learned!"
Politico
2 hours ago
- Politico
Long Covid's lingering financial side effects
LONG COVID'S TOLL — More than five years after the Covid-19 pandemic first ravaged the nation, many Americans are still dealing with the social and economic fallout of having contracted the disease. People with long Covid — those who have new or persistent symptoms lasting three months past infection — have experienced worse financial and employment outcomes, lasting up to three years after their initial infection, compared with people who haven't had the disease, according to a study published Tuesday in JAMA Network Open from researchers at Rush University Medical Center, Yale School of Medicine, Johns Hopkins University School of Medicine and other research institutions. Long Covid patients reported worse work impairment, missed work and financial distress compared with those who never had Long Covid, the study found. Vaccination against Covid was associated with improved work and economic outcomes. Not just physical: 'While much of the focus in Long COVID research has been on the medical impact, we must also consider the sustained financial burden faced by those whose symptoms persist,' lead author Michael Gottlieb, an emergency medicine doctor and vice chair of research at Rush, said in a statement. Addressing the financial burden of long Covid might 'require policy interventions, such as expanded disability benefits or workplace accommodations to help combat the work and financial impact of this condition,' the authors wrote. The researchers analyzed self-reported data from more than 3,600 participants in the Innovative Support for Patients with SARS-CoV-2 Infections Registry, a CDC-funded initiative aimed at better understanding Covid's long-term effects. Why it matters: About 6 percent of U.S. adults suffer from some form of long Covid, according to CDC estimates. The National Institutes of Health believes that as many as 23 million people have the illness, which can range in severity from mild to debilitating. The symptoms, which can include fatigue, headaches and brain fog, can be life-disrupting for many patients. Some treatments, like Paxlovid, have shown promise in reducing symptoms, but being diagnosed and finding suitable treatment can be difficult because of the disease's wide range of symptoms that often overlap with other conditions. HHS recently shut down its long Covid office, a casualty of the Trump administration's sweeping reorganization of the agency. At the time the closure was announced, an HHS employee who worked on long Covid and who was granted anonymity to share details of the move told POLITICO that abandoning work that could have cured the disease means the country's health care system will have to provide years, if not decades, of costly care for tens of millions of chronically ill people. In March, the Trump administration also canceled dozens of grants for long Covid projects, but some funding was restored after advocates fought back. WELCOME TO WEDNESDAY PULSE. I'm still reeling from Taylor Swift announcing her new album. Send your Swiftie theories, scoops and feedback to khooper@ and sgardner@ and follow along @kelhoops and @sophie_gardnerj. At the Agencies LOOMER'S LATEST PREY — After successfully ousting several members of Trump's administration for alleged insufficient loyalty, far-right activist and MAGA influencer Laura Loomer tells our colleagues at Playbook that she has her next target: Stefanie Spear, the principal deputy chief of staff and senior counselor to HHS Secretary Robert F. Kennedy Jr. The reason why, in part: 'I think that there's a clear intention by Stefanie Spear to utilize her position to try to lay the groundwork for a 2028 RFK presidential run,' Loomer alleges. Asked for comment by Playbook, a senior HHS official did not deny that Kennedy is weighing a presidential bid. Read the full story in this morning's Playbook. CDC LATEST — CDC officials held a tense all-hands meeting Tuesday in the aftermath of last week's shooting at the agency's Atlanta headquarters, Sophie reports with POLITICO's Amanda Friedman and Lauren Gardner. The meeting came as law enforcement officials revealed early Tuesday additional information about the nature of the shooting: The man who opened fire at the agency on Friday died of a self-inflicted gunshot wound and was motivated by his distrust of Covid-19 vaccines. Agency update: At the CDC's all-hands meeting, Director Susan Monarez thanked employees for their work and acknowledged that 'misinformation can be dangerous,' according to a live transcript obtained by POLITICO. 'In moments like this, we must meet the challenges with rational, evidence-based discourse spoken with compassion and understanding,' she said. 'That is how we will lead.' CDC employees were closely watching Monarez at the meeting to see how she would respond to the shooting and the news that the suspected shooter had expressed distrust of the Covid vaccine. Two CDC employees, granted anonymity to speak candidly, told POLITICO that Monarez's speech was not what they'd hoped. '[Twenty minutes] of reading off a teleprompter,' one of the employees said in a text, adding that Monarez's remarks prompted an 'overwhelmingly negative response from folks in my immediate orbit.' Another agency employee said the meeting was in stark contrast to a separate meeting held for the CDC's National Center for Immunization and Respiratory Diseases staff on Saturday, where employees could ask Monarez questions. What's next: HHS spokesperson Andrew Nixon said that staff would have 'continued opportunities' to voice their perspectives to CDC leadership in the days ahead. 'Friday's shooting was a traumatic event for the agency, and leadership is working to provide continued updates along with resources for healing and recovery,' Nixon said in a statement. DOGE SAVINGS — The Trump administration has drastically exaggerated how much money it has saved through DOGE-related cuts to federal contracts, including at health agencies, according to an analysis of public data and federal spending records from POLITICO's Jessie Blaeser. Through July, DOGE said it had saved taxpayers $52.8 billion by canceling contracts, but of the $32.7 billion in actual claimed contract savings that POLITICO could verify, DOGE's savings over that period were closer to $1.4 billion. Despite the administration's claims, none of that $1.4 billion will lower the federal deficit unless Congress steps in. Instead, the money has been returned to agencies mandated by law to spend it. The health claims: Under the VA, DOGE's wall of receipts reported savings of $932 million from contracts canceled through June, including awards for a cancer registry, suicide-prevention services and other health care support. Federal records show the VA recovered just $132 million from the awards, or less than 15 percent of what DOGE claimed, and that the VA reinstated the contract for suicide-prevention support. One of DOGE's largest savings claims is from a canceled contract for a shelter in Pecos, Texas, to house unaccompanied migrant children. In a post on social media platform X in February, DOGE said HHS 'paid ~$18M/month' to keep the now-empty center open. Canceling the agreement, it said, would translate to more than $215 million in annual savings for taxpayers. By the time the contract was added to the DOGE termination list, that savings claim skyrocketed to $2.9 billion. But HHS and its Office of Refugee Resettlement were not on track to spend anywhere close to the contract's $3.3 billion ceiling. WHAT WE'RE READING POLITICO's Tyler Katzenberger reports on a federal judge blocking the Trump administration from using Medicaid beneficiaries' personal data for immigration enforcement purposes. Bloomberg Law's Celine Castronuovo reports on Texas' attorney general accusing Eli Lilly of unlawfully pushing providers to prescribe its blockbuster obesity drugs and other treatments to receive Medicaid payments.
